论文信息 - Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors. - 字舞流文

Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.

K. McIntyre | Sidney Pitt | G. Schieven | J. Barrish | J. Tokarski | A. Fura | J. Sack | S. Nadler | W. Pitts | L. Salter-Cid | K. Gillooly | P. Carter | J. Duan | Zhonghui Lu | J. Lippy | Guoxiang Shen | J. Hynes | Hongui Wu | B. Jiang | Sylwia Stachura | Javed A Khan | S. Wrobleski | J. Kempson | R. Zhang | Rosemary F Zhang | R. Zhang

[1] R. Roskoski. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. , 2016, Pharmacological research.

[2] C. Menet,et al. Progress toward JAK1-selective inhibitors. , 2015, Future medicinal chemistry.

[3] David S. Nirschl,et al. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[4] L. Nelles,et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. , 2014, Journal of medicinal chemistry.

[5] P. Norman. Selective JAK inhibitors in development for rheumatoid arthritis , 2014, Expert opinion on investigational drugs.

[6] Mark E Flanagan,et al. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[7] M. Dowty,et al. Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[8] T. Barbui,et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.

[9] O. Grisk. Potential Benefits of Rho-kinase Inhibition in Arterial Hypertension , 2013, Current Hypertension Reports.

[10] B. Firwana,et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms , 2013, Therapeutic advances in hematology.

[11] Steven M Holland,et al. JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[12] K. Kolaja,et al. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes , 2011, Nature Reviews Drug Discovery.

[13] J. Valentin,et al. An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.

[14] J. Collins,et al. Synthesis, Characterisation and Biological Activity of Chiral Platinum(II) Complexes , 2006 .

[15] K. Leftheris,et al. N-Amination of pyrrole and indole heterocycles with monochloramine (NH2Cl). , 2004, The Journal of organic chemistry.